Clinical Trials Logo

Clinical Trial Summary

In this study the investigators will obtain histological samples from people with hereditary haemorrhagic telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome).


Clinical Trial Description

HHT is an inherited condition that leads to the development of dilated and fragile blood vessels. We propose to obtain small skin samples from patients with HHT in order to analyze the samples using histological methods, and study the properties of vascular endothelial cells derived from patients. We hypothesize that these cells will show differences when compared to normal endothelial cells, which may be confirmed in single time point analyses in histological samples. We anticipate that that these findings may help to explain aspects of the HHT disease phenotype. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00733655
Study type Observational
Source Imperial College London
Contact
Status Completed
Phase
Start date September 2008
Completion date August 2016

See also
  Status Clinical Trial Phase
Completed NCT03227263 - BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). Phase 3
Completed NCT00355108 - ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome Phase 3
Completed NCT01507480 - The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia Phase 1
Completed NCT03910244 - Pomalidomide for the Treatment of Bleeding in HHT Phase 2
Completed NCT04108052 - Diagnostic Value of Ultra-low Dose Thoracic Scanner for the Pulmonary Arteriovenous Malformation Detection in HHT Patient N/A
Recruiting NCT04976036 - Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients Phase 2
Completed NCT00684879 - Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia
Completed NCT00004648 - Studies of Hereditary Hemorrhagic Telangiectasia N/A
Completed NCT00230672 - Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs
Completed NCT03954782 - Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease. Phase 2
Completed NCT02484716 - Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO) Phase 2
Recruiting NCT00230685 - Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia
Terminated NCT02204371 - Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia Phase 2
Recruiting NCT00230620 - Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families
Recruiting NCT02157987 - Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose Phase 1/Phase 2
Completed NCT01408030 - North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Phase 2
Completed NCT00230659 - Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia
Withdrawn NCT00733629 - Study of Endothelial Cells in Patients With Hereditary Haemorrhagic Telangiectasia
Active, not recruiting NCT00230633 - Studies of White Blood Cells Derived From HHT Patients
Recruiting NCT05933330 - Hereditary Hemorrhagic Telangiectasia and Neurovascular Manifestations, in the Danish HHT Database